Metagenomi Therapeutics, Inc. (MGX): who owns it and who trades it
As of Nov 16, 2026, MGX insiders reported 13 open-market sales worth $33.1K and 2 purchases worth $23.4K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jian Irish (CEO), with $12.7K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Metagenomi Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, MGX insiders reported $23.4K of open-market purchases and $33.1K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Laurence Reid | Director | Purchase | 19,883 | $1.17 | $23.3K | Form 4 |
| Sep 9, 2026 | Laurence Reid | Director | Purchase | 117 | $1.18 | $138 | Form 4 |
| Sep 8, 2026 | Matthew Wein | See Remarks | Sale | 358 | $1.16 | $415 | Form 4 |
| Sep 8, 2026 | Jian Irish | Director | Sale | 2,140 | $1.16 | $2.5K | Form 4 |
| Sep 8, 2026 | Pamela Wapnick | CFO | Sale | 1,911 | $1.16 | $2.2K | Form 4 |
| Jun 5, 2026 | Pamela Wapnick | CFO | Sale | 2,884 | $1.30 | $3.7K | Form 4 |
| Jun 5, 2026 | Jian Irish | Director | Sale | 3,737 | $1.30 | $4.9K | Form 4 |
| Jun 5, 2026 | Matthew Wein | See Remarks | Sale | 558 | $1.30 | $725 | Form 4 |
| Mar 5, 2026 | Pamela Wapnick | CFO | Sale | 1,581 | $1.60 | $2.5K | Form 4 |
| Mar 5, 2026 | Matthew Wein | See Remarks | Sale | 482 | $1.60 | $771 | Form 4 |
| Mar 5, 2026 | Jian Irish | CEO | Sale | 1,607 | $1.60 | $2.6K | Form 4 |
| Dec 5, 2025 | Brian C. Thomas | Director | Sale | 3,830 | $1.77 | $6.8K | Form 4 |
| Dec 5, 2025 | Matthew Wein | See Remarks | Sale | 199 | $1.77 | $352 | Form 4 |
| Dec 5, 2025 | Pamela Wapnick | CFO | Sale | 1,576 | $1.77 | $2.8K | Form 4 |
| Dec 5, 2025 | Jian Irish | CEO | Sale | 1,602 | $1.77 | $2.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Laurence Reid | Director | $23.4K | – | Sep 9, 2026 |
| Jian Irish | Chief Executive Officer, Director | – | $12.7K | Sep 8, 2026 |
| Pamela Wapnick | Chief Financial Officer | – | $11.3K | Sep 8, 2026 |
| Brian C. Thomas | Director | – | $6.8K | Dec 5, 2025 |
| Matthew Wein | See Remarks | – | $2.3K | Sep 8, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MGX short interest
Low short interest. 3.5% of MGX shares are sold short: about 1 share in 28. Over the last 12 reports the number of shares short went down 26%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.33M MGX shares were sold short, 3.5% of the shares outstanding, up 2.9% from the report before. At the average daily volume of 119,432 shares, buying them all back would take about 11.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.33M | 3.52% | +3% | 119,432 | 11.1 |
| Oct 15, 2026 | 1.29M | 3.42% | +2% | 206,462 | 6.3 |
| Sep 30, 2026 | 1.27M | 3.37% | -11% | 120,626 | 10.5 |
| Sep 15, 2026 | 1.43M | 3.79% | -0% | 195,696 | 7.3 |
| Aug 31, 2026 | 1.44M | 3.80% | -1% | 135,848 | 10.6 |
| Aug 14, 2026 | 1.45M | 3.85% | -3% | 132,363 | 11.0 |
| Jul 31, 2026 | 1.49M | 3.97% | -3% | 148,142 | 10.1 |
| Jul 15, 2026 | 1.54M | 4.10% | -8% | 237,848 | 6.5 |
| Jun 30, 2026 | 1.68M | 4.48% | -4% | 144,636 | 11.6 |
| Jun 15, 2026 | 1.76M | 4.67% | -4% | 153,608 | 11.4 |
| May 29, 2026 | 1.83M | 4.87% | +1% | 198,963 | 9.2 |
| May 15, 2026 | 1.81M | 4.80% | +1% | 179,465 | 10.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Metagenomi Therapeutics company events
Metagenomi Therapeutics filed 7 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Sep 22, 2026AnnouncementShared information with investors. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jun 10, 2026LeadershipBrian C. Thomas, Ph.D. informed the board of directors of Metagenomi Therapeutics, Inc. of his resignation from his position as a member of the Board, effective as of June 9, 2026. Filing
- May 11, 2026ResultsReleased financial results. Filing
- Mar 5, 2026ResultsReleased financial results. Filing
- Jan 12, 2026RulesChanged its bylaws or articles. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Metagenomi Therapeutics financials
Famous investors that hold MGX
3 of the 50 well-known investors we track reported holding MGX in their latest 13F filing. The largest position is Jim Simons's, worth $662K.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 624,300 | $662K | 0.0% | -16% |
| Israel Englander · Millennium Management | Q3 2026 | 75,402 | $79.9K | 0.0% | -34% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 49,266 | $52.2K | 0.0% | +176% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Metagenomi Therapeutics, Inc. (MGX) stock
Are MGX insiders buying or selling?
In the last 12 months, MGX insiders reported 2 open-market purchases worth $23.4K and 13 sales worth $33.1K. The latest trade was on Sep 9, 2026. See every trade.
What is the short interest in MGX?
As of Oct 30, 2026, 1.33M MGX shares were sold short, 3.5% of the shares outstanding, up 2.9% from the report before. At the average daily volume of 119,432 shares, buying them all back would take about 11.1 trading days (days to cover). See the history.
Which famous investors hold MGX?
3 of the 50 well-known investors we track reported MGX in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $662K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.